All Updates

All Updates

icon
Filter
Partnerships
Clearmind Medicine enters licensing agreement with Yissum for psychedelic compounds development for PTSD treatment
Psychedelic Medicine
May 7, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

May 7, 2024

Clearmind Medicine enters licensing agreement with Yissum for psychedelic compounds development for PTSD treatment

Partnerships

  • Clearmind Medicine, a Vancouver-based psychedelic drugs company, has entered a patent licensing agreement with Yissum Research Development Company at the Hebrew University of Jerusalem. The collaboration focuses on developing and utilizing psychedelic compounds to treat post-traumatic stress disorder (PTSD) and other mental health illnesses.

  • Under the terms of the agreement, Clearmind gains exclusive global rights to develop, manufacture, and commercialize novel compounds invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel from the Hebrew University. Clearmind assumes responsibility for further development and potential commercialization while adhering to regulations. Terms of the agreement also include future milestone payments, royalties on sales, and commitments to safeguard patents.

  • Analyst QuickTake: This partnership follows a prior collaboration with Yissum in April 2024 aimed at developing psychedelic compounds for addiction and mental health disorders.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.